FDA clears AZ's Imfinzi for aggressive lung cancer
AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).
Newsletters and Deep Dive digital magazine
AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).
Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer
As the incidence of cancer rises around the world, the demand for faster, more precise diagnoses is also on the rise.
Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.
Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies.1
Editor's Picks
Newsletters and Deep Dive
digital magazine